Product news

Share this article:

Boehringer Ingelheim Pharmaceuticals announced that the FDA has granted full approval of Aptivus (tipranavir) capsules. The full approval of Aptivus based largely on 48-week analyses of the Phase III pivotal clinical studies known as the RESIST (Randomized Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir) trials. These trials comprise one of the largest study programs conducted in treatment-experienced HIV patients. The FDA granted accelerated approval to Aptivus in June 2005. Accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters